Insulin Resistance in Non-alcoholic Fatty Liver Disease

US Department of Veterans Affairs (VA)

Status: Terminated

Conditions: Fatty Liver; Insulin Resistance

Treatments: Drug: placebo for fenofibrate; Drug: rosiglitazone; Drug: fenofibrate; Drug: placebo for rosiglitazone

Study type: Interventional

Funder types: Other U.S. Federal agency

Identifiers

NCT00252499

CDA-2-044-08S

Details and patient eligibility

About

The purpose of this study is to determine whether nonalcoholic fatty liver disease (NAFLD) is associated with altered peripheral and hepatic insulin sensitivity and to investigate potential mechanisms underlying insulin resistance in NAFLD by determining associations between hepatic and peripheral insulin sensitivity, hepatic steatosis, dyslipidemia, inflammatory cytokines, glucose metabolism, beta-cell function and body fat distribution.

Full description

NAFLD and nonalcoholic steatohepatitis (NASH) are common liver disorders that are strongly associated with obesity, type 2 diabetes and dyslipidemia. The underlying pathophysiology of fatty infiltration of the liver is thought to be related to insulin resistance, which is an almost universal finding in patients with NAFLD. It is also possible that fat infiltration and inflammation in the liver may impair insulin sensitivity, either locally in the liver, or peripherally via the actions of inflammatory cytokines. We hypothesize that insulin resistance is a major causal factor leading to fat deposition in the liver and NAFLD, and thus interventions aimed at improving insulin sensitivity will result in a reduction of hepatic inflammation and steatosis.

Specific Aim 1: To determine in a cross-sectional study whether NAFLD is associated with altered peripheral and hepatic insulin sensitivity and to study their relationships with hepatic steatosis, dyslipidemia, inflammatory cytokines, glucose metabolism, -cell function and body fat distribution. Specific Aim 2: To determine in a 6 month placebo-controlled double-blinded treatment study if treatment with rosiglitazone, an insulin sensitizer, or fenofibrate, a triglyceride lowering agent, will improve both hepatic as well as peripheral insulin sensitivity and thereby improve hepatic steatosis and inflammation in subjects with NAFLD.

The results of the proposed study will have important implications for our understanding of the mechanisms underlying insulin resistance and abnormalities in lipid and glucose metabolism in subjects with NAFLD and for the design of future studies aimed at the prevention and treatment of this condition.

Enrollment: 13 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age 18-80 years old Controls:

  • otherwise healthy Case subjects: NAFLD on liver biopsy within the past 3 years or presumed NAFLD with otherwise unexplained elevated ALT and fatty liver by CT or ultrasound

• Able to comply with taking 3 pills a day for 6 months and follow-up safety visits

Exclusion criteria

• Controls:

  • history or evidence of hepatic steatosis

• Cases:

  • Cirrhosis on liver biopsy or by clinical exam or fibrosis score
  • Causes of liver dysfunction other than NASH

• Use of medications associated with hepatic steatosis:

  • glucocorticoids
  • estrogens
  • tamoxifen
  • amiodarone
  • accutane
  • sertraline

• Use of medications that cause insulin resistance:

  • niacin
  • glucocorticoids
  • anti-HIV drugs or atypical antipsychotics

• Use of lipid-lowering medications except stable dose statin

• Use of anti-NASH drugs such as:

  • ursodeoxycholic acid
  • betaine milk thistle

• Use of coumadin

• Use of nitrates

• Significant alcohol consumption:

  • Average >20 grams/day

• In subjects with diabetes

  • a HbA1c >7.5% or use of insulin
  • metformin
  • rosiglitazone or pioglitazone

• Liver transaminases:

  • Cases: ALT >5x upper limit of normal
  • Controls: ALT or AST above the normal range

• Iron saturation >50%

• Creatinine >1.5 mg/dl for men and >1.4 mg/dl for women

• Hematocrit <33%

• Pregnancy or lactation

• Significant weight loss within the past 6 months for controls, or since the liver biopsy for case subjects, history of significant coronary artery disease or congestive heart failure

• Retinopathy

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

13 participants in 3 patient groups, including a placebo group

Placebo Arm

Placebo Comparator group

Description:

matching placebo for rosiglitazone, 1 po bid and placebo for fenofibrate 1 po qd

Treatment:

Drug: placebo for rosiglitazone

Drug: placebo for fenofibrate

Rosiglitazone Arm

Experimental group

Description:

rosiglitazone 4 mg po bid and fenofibrate placebo 1 po qd

Treatment:

Drug: rosiglitazone

Drug: placebo for fenofibrate

Fenofibrate Arm

Experimental group

Description:

micronized fenofibrate 200 mg 1 po qd and rosiglitazone placebo 1 po bid

Treatment:

Drug: fenofibrate

Drug: placebo for rosiglitazone